The food and Drug Administration has been studying whether it could approve generic versions of insulin and human growth hormone, triggering an objection from the biotechnology industry while Fueling speculation that the government may be inching closer to allowing generic competition for Bioengineered drugs.
Biotech industry wary of generics rise.